Detection and care of familial hypercholesterolaemia in the community: is there a role for the pharmacist?
- 339 Downloads
Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma cholesterol and premature coronary heart disease. It is estimated that there are at 40 million people with FH worldwide, but most remain unrecognised and inadequately treated. To bridge this gap in coronary prevention several guidelines on detecting and managing FH have been published. We briefly review these and comment on the potential role of pharmacists in case detection, point-of-care testing and pharmacotherapy.
KeywordsCare models Cascade screening Familial hypercholesteroleamia Pharmacist role Screening
Conflicts of interest
- 5.National Institute for Health and Clinical Excellence, The National Collaborating Centre for Primary Care. NICE Clinical Guideline 71: Identification and management of familial hypercholesterolaemia. 2008 [cited 2011]; Available from: www.nice.org.uk/nicemedia/pdf/CG071NICEGuideline.pdf.
- 7.Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial hypercholesterolemia. J Clin Lipidol. 2011; 5:133–40.Google Scholar
- 8.The Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report. Pediatrics. 2011; 28 Suppl 5:S213–S56.Google Scholar
- 9.Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, Lebrethon MC, et al. Management of familial hypercholesterolemia in children and young adults: Consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis. 2011;218:272–80.PubMedCrossRefGoogle Scholar
- 13.FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. [cited 2012]; Available from: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm.
- 14.Preiss D, Sattar N. Pharmacotherapy: statins and new-onset diabetes: the important questions. Nat Rev Cardiol. 2012;Advance online publication.Google Scholar
- 17.Yamada C, Johnson JA, Robertson PP, Tsuyuki RT. Long-term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events: extended follow-up of the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus). Pharmacotherapy. 2005;25:110–5.PubMedCrossRefGoogle Scholar
- 18.Smith JD, Battye K, Roufeil L, Mitchell C, White C, Veitch C, et al. Research to track the rural pharmacy workforce and identify the role that rural programs have on retention of the rural pharmacy workforce. In: Ageing DoHa, editor, Pharmacy Guild of Australia; 2010.Google Scholar
- 23.Charrois TC, Zolezzi M, Koshman L, Pearson SL, Makowsky G, Durec M, et al. A systematic review of the evidence for pharmacist care of patients with dyslipidaemia. Pharmacotherapy. J Human Pharmacol Drug Therapy. 2012;32:222–33.Google Scholar
- 26.Pedersen KMV, Humphries SE, Roughton M, Besford JS. The National Audit of the Management of Familial Hypercholesterolaemia 2010: Full report. [cited; Available from: www.rcplondon.ac.uk/node/2584.